Skip to main content

Table 2 Association of terminal duct lobular unit involution with breast tumor subtypes among overall cases

From: Age-related terminal duct lobular unit involution in benign tissues from Chinese breast cancer patients with luminal and triple-negative tumors

 

Overall (n = 504)

Luminal A (n = 254)

TN/CBP (n = 250)

TN/CBP vs. luminal A

CBP (n = 125)

CBP vs. luminal A

OR (95% CI)a

P valuea

OR (95% CI)a

P valuea

TDLU count/100 mm2

 Median (IQR)

18.3

(9–35)

37

(18.0–65.0)

42

(20.0–75.0)

  

46

(20–75)

  

 Tertile 1

168

33.3

87

34.3

81

32.4

Reference

 

41

32.8

Reference

 

 Tertile 2

168

33.3

87

34.3

81

32.4

0.83 (0.47–1.49)

0.14

40

32.0

0.83 (0.41–1.67)

0.18

 Tertile 3

168

33.3

80

31.5

88

35.0

1.44 (0.77–2.70)

0.09

44

35.2

1.23 (0.71–3.28)

0.11

 ORtrend/P trend

      

1.18 (0.86– 1.62)

0.31

  

1.24 (0.84– 1.82)

0.28

Maximum TDLU span (μm)

 Median (IQR)

775

(589.5–1023.0)

764.5

(600.0–992.0)

803

(588.0–1043.0)

  

809

(624.0–1100.0)

  

 Tertile 1

168

33.3

83

32.7

85

34.0

Reference

 

39

31.2

Reference

 

 Tertile 2

169

33.5

91

35.8

78

31.2

0.69 (0.39–1.22)

0.05

38

30.4

0.78 (0.39–1.57)

0.12

 Tertile 3

167

33.1

80

31.5

87

34.8

1.25 (0.67–2.30)

0.13

48

38.4

1.53 (0.73–3.18)

0.08

 ORtrend/P trend

      

1.12 (0.82– 1.52)

0.48

  

1.26 (0.87– 1.82)

0.22

Maximum category of acini count/TDLU

 Median (IQR)

3

(2.0–4.0)

3

(2.0–4.0)

3

(2.0–5.0)

  

3

(2.0–5.0)

  

 Tertile 1

176

34.9

97

38.2

79

31.6

Reference

 

39

31.2

Reference

 

 Tertile 2

211

41.9

103

40.6

108

43.2

1.57 (0.89–2.77)

0.70

47

37.6

1.24 (0.62–2.47)

0.27

 Tertile 3

117

23.2

54

21.3

63

25.2

2.06 (1.03–4.11)

0.09

39

31.2

2.89 (1.27–6.55)

0.006

 ORtrend/P trend

      

1.42 (1.01– 2.01)

0.045

  

1.69 (1.12– 2.55)

0.012

  1. Abbreviations: CBP Core basal phenotype, TDLU Terminal duct lobular unit, TN Triple-negative
  2. aORs, 95% CIs, and P values were obtained from logistic regression analyses comparing cases with TN/CBP tumors or CBP tumors only with cases with luminal A tumors, adjusted for age (5-year intervals), body mass index (<23, 23–24.9, 25–29.9, or 30+ kg/m2), parity (nulliparous, one child, or more than one child) and grade (well, moderately, or poorly differentiated)